H.R. 383 · 118th Congress (2023–2025)
To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.
This bill nullifies certain changes made by the Food and Drug Administration (FDA) to dispensing requirements for mifepristone. (Mifepristone is a drug that is approved to end pregnancies through 10 weeks gestation when used in conjunction with the drug misoprostol. The procedure is often referred to as medication abortion or the abortion pill.)
The FDA regulates the use of mifepristone through the Mifepristone Risk Evaluation and Mitigation Strategy (REMS) program. The program requires health care providers to comply with certain requirements in order to prescribe or dispense mifepristone to end a pregnancy; the program previously included an in-person dispensing requirement that required mifepristone to be directly dispensed to patients in clinics, medical offices, or hospitals. During the COVID-19 public health emergency, the FDA temporarily stopped enforcing the in-person dispensing requirement, which allowed mail-order pharmacies to fill and dispense mifepristone prescriptions.
In January 2023, the FDA modified program requirements so as to (1) remove the in-person dispensing requirement, and (2) require pharmacies to be certified in the program in order to dispense mifepristone. The modifications allow retail pharmacies, after receiving certification, to dispense mifepristone pursuant to prescriptions that are written by program-certified prescribers.
The bill nullifies the January 2023 changes and prohibits any similar changes in the future.
Expired in House committee
Derived from the legislative history, not an official disposition.
Latest actionReferred to Health
This bill’s path
This is H.R. 383’s recorded path, not a universal congressional workflow.
How bills become lawAll actionsIntroduced
Passed House
Passed Senate
Sent to President
Signed into law
Expired
- Sponsor
- Rep. Diana Harshbarger (R-TN-1)
- Cosponsors
26 cosponsors
13 original · 13 later
26 R
- Rep. Jim Banks (R-IN-3)· Original · Jan 17, 2023
- Rep. James R. Baird (R-IN-4)· Original · Jan 17, 2023
- Rep. Earl L. "Buddy" Carter (R-GA-1)· Original · Jan 17, 2023
- Rep. Jeff Duncan (R-SC-3)· Original · Jan 17, 2023
- Rep. Randy Feenstra (R-IA-4)· Original · Jan 17, 2023
- Rep. Paul A. Gosar (R-AZ-9)· Original · Jan 17, 2023
- Rep. Kevin Hern (R-OK-1)· Original · Jan 17, 2023
- Rep. Ronny Jackson (R-TX-13)· Original · Jan 17, 2023
- Rep. Doug Lamborn (R-CO-5)· Original · Jan 17, 2023
- Rep. Mary E. Miller (R-IL-15)· Original · Jan 17, 2023
- Rep. Christopher H. Smith (R-NJ-4)· Original · Jan 17, 2023
- Rep. Daniel Webster (R-FL-11)· Original · Jan 17, 2023
- Rep. Randy K. Weber, Sr. (R-TX-14)· Original · Jan 17, 2023
- Rep. Lauren Boebert (R-CO-3)· Later · Jan 24, 2023
- Rep. Mike Flood (R-NE-1)· Later · Jan 24, 2023
- Rep. Glenn Grothman (R-WI-6)· Later · Jan 24, 2023
- Rep. John R. Moolenaar (R-MI-2)· Later · Jan 24, 2023
- Rep. Pete Sessions (R-TX-17)· Later · Jan 24, 2023
- Rep. Mike Bost (R-IL-12)· Later · Jan 26, 2023
- Rep. Tony Gonzales (R-TX-23)· Later · Jan 26, 2023
- Rep. Brian J. Mast (R-FL-21)· Later · Jan 26, 2023
- Rep. Rudy Yakym III (R-IN-2)· Later · Jan 26, 2023
- Rep. Michael Guest (R-MS-3)· Later · Feb 6, 2023
- Rep. Anna Paulina Luna (R-FL-13)· Later · Mar 8, 2023
- Rep. Clay Higgins (R-LA-3)· Later · Mar 17, 2023
- Rep. Robert B. Aderholt (R-AL-4)· Later · Aug 11, 2023
- Policy area
- Health
On this page
Timeline
i
In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.
Introduced in House
Document: Introduced in House
Sources
- Congress.gov actionIntro-H
- Library of Congress
- Latest
▸ 2 committee actions · Jan 17, 2023 – Jan 27, 2023
Referred to committee
Referred to the House Committee on Energy and Commerce.
Sources
- Congress.gov action
- House floor actions
Referred to Health
Referred to the Subcommittee on Health.
Sources
- Congress.gov action
- House committee actions
Expired
Introduced → Referred to House Health → No further action before the 118th Congress ended.
Committees
Text & titles
i
Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.
| Version | Date | Links |
|---|---|---|
| Introduced in House |
Titles (1)
To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.
Display title, Official title · Introduced in House